NASDAQ:ZNTL Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis $2.96 -0.28 (-8.64%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.95▼$3.3250-Day Range$2.90▼$4.5752-Week Range$2.83▼$25.45Volume748,208 shsAverage Volume1.02 million shsMarket Capitalization$210.24 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Zentalis Pharmaceuticals alerts: Email Address Zentalis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.30 Rating ScoreUpside/Downside282.9% Upside$11.33 Price TargetShort InterestBearish16.29% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.95) to ($3.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.94 out of 5 starsMedical Sector787th out of 910 stocksPharmaceutical Preparations Industry368th out of 426 stocks 4.2 Analyst's Opinion Consensus RatingZentalis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 3 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageZentalis Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zentalis Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.29% of the outstanding shares of Zentalis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverZentalis Pharmaceuticals has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Zentalis Pharmaceuticals has recently increased by 2.30%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldZentalis Pharmaceuticals does not currently pay a dividend.Dividend GrowthZentalis Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZNTL. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Zentalis Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Zentalis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zentalis Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.10% of the stock of Zentalis Pharmaceuticals is held by insiders.Read more about Zentalis Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zentalis Pharmaceuticals are expected to decrease in the coming year, from ($2.95) to ($3.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zentalis Pharmaceuticals is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zentalis Pharmaceuticals is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZentalis Pharmaceuticals has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Zentalis Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.Read More ZNTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZNTL Stock News HeadlinesSeptember 3, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 28, 2024 | americanbankingnews.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $11.33 Consensus Target Price from AnalystsSeptember 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.August 28, 2024 | americanbankingnews.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $11.33 Average Price Target from AnalystsAugust 20, 2024 | stockhouse.comNewman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. - ZNTLAugust 15, 2024 | globenewswire.comZentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAugust 13, 2024 | msn.comWedbush Upgrades Zentalis Pharmaceuticals (ZNTL)August 12, 2024 | markets.businessinsider.comOptimistic Outlook for Zentalis Pharmaceuticals Amidst Clinical Progress and Market OpportunitiesSeptember 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.August 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zentalis Pharmaceuticals Amidst Clinical Progress and Regulatory OptimismAugust 9, 2024 | globenewswire.comZentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAugust 9, 2024 | globenewswire.comZentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational ProgressAugust 4, 2024 | globenewswire.comZentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAugust 3, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLAugust 2, 2024 | prnewswire.comZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law FirmAugust 1, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLAugust 1, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLSee More Headlines Receive ZNTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZNTL CUSIPN/A CIK1725160 Webwww.zentalis.com Phone212-433-3791FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$11.33 High Stock Price Target$25.00 Low Stock Price Target$4.00 Potential Upside/Downside+282.9%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-292,190,000.00 Net MarginsN/A Pretax Margin-479.32% Return on Equity-44.22% Return on Assets-35.61% Debt Debt-to-Equity RatioN/A Current Ratio6.59 Quick Ratio6.59 Sales & Book Value Annual Sales$40.56 million Price / Sales5.18 Cash FlowN/A Price / Cash FlowN/A Book Value$5.38 per share Price / Book0.55Miscellaneous Outstanding Shares71,026,000Free Float66,693,000Market Cap$210.24 million OptionableOptionable Beta1.70 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Kimberly Lynn Blackwell M.D. (Age 55)CEO & Director Comp: $1.17MMr. Cameron S. Gallagher M.B.A. (Age 54)Co-Founder, President, Interim CFO, Interim Treasurer & Director Comp: $892.15kMs. Andrea Paul J.D. (Age 43)Chief Legal Officer & Corporate Secretary Comp: $682.47kDr. Diana F. Hausman M.D. (Age 61)Chief Medical Officer & Director Comp: $38.44kMr. Vincent Vultaggio (Age 41)VP of Finance & Interim Principal Accounting Officer Dr. Mark Lackner Ph.D. (Age 56)Chief Scientific Officer Ms. Kimberly FreemanChief Strategy OfficerDr. Kyle Rasbach Ph.D. (Age 44)Pharm.D., Chief Business Officer Dr. Adrian Jubb M.D.Ph.D., Executive Vice President of Clinical DevelopmentMore ExecutivesKey CompetitorsPrelude TherapeuticsNASDAQ:PRLDCryoportNASDAQ:CYRXIronwood PharmaceuticalsNASDAQ:IRWDArriVent BioPharmaNASDAQ:AVBPRelay TherapeuticsNASDAQ:RLAYView All CompetitorsInsiders & InstitutionsAlgert Global LLCBought 19,119 shares on 8/16/2024Ownership: 0.027%Decheng Capital LLCBought 970,859 shares on 8/15/2024Ownership: 4.323%Squarepoint Ops LLCBought 125,649 shares on 8/14/2024Ownership: 0.209%Bank of Montreal CanBought 98,331 shares on 8/14/2024Ownership: 0.138%Profund Advisors LLCSold 15,510 shares on 8/14/2024Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions ZNTL Stock Analysis - Frequently Asked Questions How have ZNTL shares performed this year? Zentalis Pharmaceuticals' stock was trading at $15.15 at the start of the year. Since then, ZNTL shares have decreased by 80.5% and is now trading at $2.96. View the best growth stocks for 2024 here. How were Zentalis Pharmaceuticals' earnings last quarter? Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) posted its quarterly earnings results on Friday, August, 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by $0.40. When did Zentalis Pharmaceuticals IPO? Zentalis Pharmaceuticals (ZNTL) raised $131 million in an initial public offering on Friday, April 3rd 2020. The company issued 7,700,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO. Who are Zentalis Pharmaceuticals' major shareholders? Zentalis Pharmaceuticals' top institutional investors include Decheng Capital LLC (4.32%), Primecap Management Co. CA (1.74%), Renaissance Technologies LLC (0.93%) and Dimensional Fund Advisors LP (0.88%). Insiders that own company stock include Matrix Capital Management Comp, Anthony Y Sun, Cam Gallagher, Melissa B Epperly, Diana Hausman, Kimberly Blackwell, David Michael Johnson, Carrie Brownstein, Jan Skvarka, Kevin D Bunker, Dimitris Voliotis and Alexis Pinto. View institutional ownership trends. How do I buy shares of Zentalis Pharmaceuticals? Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Zentalis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zentalis Pharmaceuticals investors own include Esperion Therapeutics (ESPR), Zogenix (ZGNX), AbbVie (ABBV), Advanced Micro Devices (AMD), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY) and Clovis Oncology (CLVS). This page (NASDAQ:ZNTL) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
